Chemistry Reference
In-Depth Information
This opens up the possibility of rigorously assigning likelihoods to the NOE assignments
obtained from NOE matching, which in turn will facilitate the development iterative pose
refinement strategies.
In conclusion, we expect that NOE matching will contribute significantly to our future
drug discovery efforts and that the continued development of NOEmatching and associated
algorithms and technologies will keep us busy for some considerable time to come.
References
[1] Shuker, S. B., Hajduk, P. J., Meadows, R. P. and Fesik, S. W. (1996). Discovering high-affinity
ligands for proteins: SAR by NMR.
Science
274
, 1531-1534.
[2] Hajduk, P. J. and Greer, J. (2007). A decade of fragment-based drug design: strategic advances
and lessons learned.
Nat. Rev. Drug Discov.
6
, 211-219.
[3] Hann, M. M., Leach, A. R. and Harper, G. (2001). Molecular complexity and its impact on the
probability of finding leads for drug discovery.
J. Chem. Inf. Comput. Sci
.
41
, 856-864.
[4] Oprea, T. I., Davis, A. M., Teague, S. J. and Leeson, P. D. (2001). Is there a difference between
leads and drugs? A historical perspective.
J. Chem. Inf. Comput. Sci
.
41
, 1308-1315.
[5] Anderson, A. C. (2003). The process of structure-based drug design.
Chem. Biol.
10
,
787-797.
[6] Vajda, S. and Guarnieri, F. (2006). Characterization of protein-ligand interaction sites using
experimental and computational methods.
Curr. Opin. Drug Discov. Dev
.
9
, 354-362.
[7] Muchmore, S. W. and Hajduk, P. J. (2003). Crystallography, NMR and virtual screening:
Integrated tools for drug discovery.
Curr. Opin. Drug Discov. Dev
.
6
, 544-549.
[8] Villar, H. O., Yan, J. and Hansen, M. R. (2004). Using NMR for ligand discovery and
optimization.
Curr. Opin. Chem. Biol
.
8
, 387-391.
[9] Nienaber, V. L., Richardson, P. L., Klighofer, V., Bouska, J. J., Giranda, V. L. and Greer, J.
(2000). Discovering novel ligands for macromolecules using X-ray crystallographic screening.
Nat. Biotechnol.
18
, 1105-1108.
[10] Lesuisse, D., Lange, G., Deprez, P., Benard, D., Schoot, B., Delettre, G., Marquette, J.-P.,
Broto, P., Jean-Baptiste, V., Bichet, P., Sarubbi, E. and Mandine, E. (2002). SAR and X-ray. A
new approach combining fragment-based screening and rational drug design: application to the
discovery of nanomolar inhibitors of Src SH2.
J. Med. Chem
.
45
, 2379-2387.
[11] Hartshorn, M. J., Murray, C. W., Cleasby, A., Frederickson, M., Tickle, I. J. and Jhoti, H. (2005).
Fragment-based lead discovery using X-ray crystallography.
J. Med. Chem
.
48
, 403-413.
[12] Petros, A. M., Dinges, J., Augeri, D. J., Baumeister, S. A., Betebenner, D. A., Bures, M. G.,
Elmore, S. W., Hajduk, P. J., Joseph, M. K., Landis, S. K., Nettesheim, D. G., Rosenberg, S. H.,
Shen, W., Thomas, S., Wang, X., Zanze, I., Zhang, H. and Fesik, S. W. (2006). Discovery of a
potent inhibitor of the antiapoptotic protein Bcl-x
L
from NMR and parallel synthesis.
J. Med.
Chem.
49
, 656-663.
[13] Hajduk, P. J., Sheppard, G., Nettesheim, D. G., Olejniczak, E. T., Shuker, S. B., Meadows, R. P.,
Steinman, D. H., Carrera, G. M., Jr, Marcotte, P. A., Severin, J., Walter, K., Smith, H., Gubbins,
E., Simmer, R., Holzman, T. F., Morgan, D. W., Davidsen, S. K., Summers, J. B. and Fesik, S.
W. (1997). Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR.
J.
Am. Chem. Soc
.
119
, 5818-5827.
[14] Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A.,
Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., Joseph, M. K., Kitada, S., Korsmeyer,
S. J., Kunzer, A. R., Letai, A., Li, C., Mitten, M. J., Nettesheim, D. G., Ng, S. C., Nimmer, P. M.,
O'Connor, J. M., Oleksijew, A., Petros, A. M., Reed, J. C., Shen, W., Tahir, S. K., Thompson,
